Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

Identifieur interne : 002869 ( Main/Exploration ); précédent : 002868; suivant : 002870

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

Auteurs : Maarten Boers [Pays-Bas] ; Arco C. Verhoeven [Pays-Bas] ; Harry M. Markusse [Pays-Bas] ; Mart Afj Van De Laar [Pays-Bas] ; Rene Westhovens [Belgique] ; J Christiaan Van Denderen [Pays-Bas] ; Derkjen Van Zeben ; Ben Ac Dijkmans [Pays-Bas] ; Andre J. Peeters ; Piet Jacobs ; Hans R. Van Den Brink [Pays-Bas] ; Hubert Ja Schouten [Pays-Bas] ; Dsire Mfm Van Der Heijde [Pays-Bas] ; Annelies Boonen [Pays-Bas] ; Sjef Van Der Linden [Belgique]

Source :

RBID : ISTEX:F5B9214CDA21717C12528C07FBCFABD67ECA8770

English descriptors

Abstract

Summary: Background The value of intensive combination therapy in early rheumatoid arthritis is unproven. In a multicentre, double-blind, randomised trial (COBRA), we compared the combination of sulphasalazine (2 g/day), methotrexate (75 mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 75 mg/day) with sulphasalazine alone.Methods 155 patients with early rheumatoid arthritis (median duration 4 months) were randomly assigned combined treatment (76) or sulphasalazine alone (79). Prednisolone and methotrexate were tapered and stopped after 28 and 40 weeks, respectively. The main outcomes were the pooled index (a weighted change score of five disease activity measures) and the Sharp/Van der Heijde radiographic damage score in hands and feet. Independent health-care professionals assessed the main outcomes without knowledge of treatment allocation.Findings At week 28, the mean pooled index was 14 (95 CI 1216) in the combined treatment group and 08 (0610) in the sulphasalazine group (p<00001). At this time, 55 (72) and 39 (49) patients, respectively, were improved according to American College of Rheumatology criteria. The clinical difference between the groups decreased and was no longer significant after prednisolone was stopped, and there were no further changes after methotrexate was stopped. At 28 weeks, the radiographic damage score had increased by a median of 1 (range 028) in the combined-therapy group and 4 (044) in the sulphasalazine group (p<00001). The increases at week 56 (2 [043] vs6 [054], p=0004), and at week 80 (4 [080] vs 12 [072], p=001) were also significant. Further analysis suggests that combined therapy immediately suppressed damage progression, whereas sulphasalazine did so less effectively and with a lag of 6 to 12 months. There were fewer withdrawals in the combined therapy than the sulphasalazine group (6 [8] vs 23 [29]), and they occurred later.Interpretation This combined-therapy regimen offers additional disease control over and above that of sulphasalazine alone that persists for up to a year after corticosteroids are stopped. Although confirmatory studies and long-term follow-up are needed, this approach may prove useful in the treatment of early rheumatoid arthritis.

Url:
DOI: 10.1016/S0140-6736(97)01300-7


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis</title>
<author>
<name sortKey="Boers, Maarten" sort="Boers, Maarten" uniqKey="Boers M" first="Maarten" last="Boers">Maarten Boers</name>
</author>
<author>
<name sortKey="Verhoeven, Arco C" sort="Verhoeven, Arco C" uniqKey="Verhoeven A" first="Arco C" last="Verhoeven">Arco C. Verhoeven</name>
</author>
<author>
<name sortKey="Markusse, Harry M" sort="Markusse, Harry M" uniqKey="Markusse H" first="Harry M" last="Markusse">Harry M. Markusse</name>
</author>
<author>
<name sortKey="Van De Laar, Mart Afj" sort="Van De Laar, Mart Afj" uniqKey="Van De Laar M" first="Mart Afj" last="Van De Laar">Mart Afj Van De Laar</name>
</author>
<author>
<name sortKey="Westhovens, Rene" sort="Westhovens, Rene" uniqKey="Westhovens R" first="Rene" last="Westhovens">Rene Westhovens</name>
</author>
<author>
<name sortKey="Van Denderen, J Christiaan" sort="Van Denderen, J Christiaan" uniqKey="Van Denderen J" first="J Christiaan" last="Van Denderen">J Christiaan Van Denderen</name>
</author>
<author>
<name sortKey="Van Zeben, Derkjen" sort="Van Zeben, Derkjen" uniqKey="Van Zeben D" first="Derkjen" last="Van Zeben">Derkjen Van Zeben</name>
</author>
<author>
<name sortKey="Dijkmans, Ben Ac" sort="Dijkmans, Ben Ac" uniqKey="Dijkmans B" first="Ben Ac" last="Dijkmans">Ben Ac Dijkmans</name>
</author>
<author>
<name sortKey="Peeters, Andre J" sort="Peeters, Andre J" uniqKey="Peeters A" first="Andre J" last="Peeters">Andre J. Peeters</name>
</author>
<author>
<name sortKey="Jacobs, Piet" sort="Jacobs, Piet" uniqKey="Jacobs P" first="Piet" last="Jacobs">Piet Jacobs</name>
</author>
<author>
<name sortKey="Van Den Brink, Hans R" sort="Van Den Brink, Hans R" uniqKey="Van Den Brink H" first="Hans R" last="Van Den Brink">Hans R. Van Den Brink</name>
</author>
<author>
<name sortKey="Schouten, Hubert Ja" sort="Schouten, Hubert Ja" uniqKey="Schouten H" first="Hubert Ja" last="Schouten">Hubert Ja Schouten</name>
</author>
<author>
<name sortKey="Van Der Heijde, Dsire Mfm" sort="Van Der Heijde, Dsire Mfm" uniqKey="Van Der Heijde D" first="Dsire Mfm" last="Van Der Heijde">Dsire Mfm Van Der Heijde</name>
</author>
<author>
<name sortKey="Boonen, Annelies" sort="Boonen, Annelies" uniqKey="Boonen A" first="Annelies" last="Boonen">Annelies Boonen</name>
</author>
<author>
<name sortKey="Van Der Linden, Sjef" sort="Van Der Linden, Sjef" uniqKey="Van Der Linden S" first="Sjef" last="Van Der Linden">Sjef Van Der Linden</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F5B9214CDA21717C12528C07FBCFABD67ECA8770</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1016/S0140-6736(97)01300-7</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-Z6J6QRTW-5/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000512</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000512</idno>
<idno type="wicri:Area/Istex/Curation">000512</idno>
<idno type="wicri:Area/Istex/Checkpoint">001662</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001662</idno>
<idno type="wicri:doubleKey">0140-6736:1997:Boers M:randomised:comparison:of</idno>
<idno type="wicri:Area/Main/Merge">002918</idno>
<idno type="wicri:Area/Main/Curation">002869</idno>
<idno type="wicri:Area/Main/Exploration">002869</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis</title>
<author>
<name sortKey="Boers, Maarten" sort="Boers, Maarten" uniqKey="Boers M" first="Maarten" last="Boers">Maarten Boers</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>University Hospital, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Verhoeven, Arco C" sort="Verhoeven, Arco C" uniqKey="Verhoeven A" first="Arco C" last="Verhoeven">Arco C. Verhoeven</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>University Hospital, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Markusse, Harry M" sort="Markusse, Harry M" uniqKey="Markusse H" first="Harry M" last="Markusse">Harry M. Markusse</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Zuiderziekenhuis, Rotterdam</wicri:regionArea>
<placeName>
<settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Van De Laar, Mart Afj" sort="Van De Laar, Mart Afj" uniqKey="Van De Laar M" first="Mart Afj" last="Van De Laar">Mart Afj Van De Laar</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Medisch Spectrum Twente and Twenteborg Hospital, Enschede and Almelo</wicri:regionArea>
<wicri:noRegion>Enschede and Almelo</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Westhovens, Rene" sort="Westhovens, Rene" uniqKey="Westhovens R" first="Rene" last="Westhovens">Rene Westhovens</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Pellenberg Hospital, Catholic University, Louvain</wicri:regionArea>
<wicri:noRegion>Louvain</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Van Denderen, J Christiaan" sort="Van Denderen, J Christiaan" uniqKey="Van Denderen J" first="J Christiaan" last="Van Denderen">J Christiaan Van Denderen</name>
<affiliation wicri:level="3">
<country>Pays-Bas</country>
<placeName>
<settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
<wicri:orgArea>Jan van Breemen Instituut</wicri:orgArea>
</affiliation>
</author>
<author>
<name sortKey="Van Zeben, Derkjen" sort="Van Zeben, Derkjen" uniqKey="Van Zeben D" first="Derkjen" last="Van Zeben">Derkjen Van Zeben</name>
<affiliation>
<wicri:noCountry code="subField">Hague</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Dijkmans, Ben Ac" sort="Dijkmans, Ben Ac" uniqKey="Dijkmans B" first="Ben Ac" last="Dijkmans">Ben Ac Dijkmans</name>
<affiliation wicri:level="3">
<country>Pays-Bas</country>
<placeName>
<settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
<wicri:orgArea>University Hospital</wicri:orgArea>
</affiliation>
</author>
<author>
<name sortKey="Peeters, Andre J" sort="Peeters, Andre J" uniqKey="Peeters A" first="Andre J" last="Peeters">Andre J. Peeters</name>
<affiliation>
<wicri:noCountry code="subField">Delft</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Jacobs, Piet" sort="Jacobs, Piet" uniqKey="Jacobs P" first="Piet" last="Jacobs">Piet Jacobs</name>
<affiliation>
<wicri:noCountry code="subField">Roermond</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Van Den Brink, Hans R" sort="Van Den Brink, Hans R" uniqKey="Van Den Brink H" first="Hans R" last="Van Den Brink">Hans R. Van Den Brink</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Medisch Centrum Alkmaar</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Schouten, Hubert Ja" sort="Schouten, Hubert Ja" uniqKey="Schouten H" first="Hubert Ja" last="Schouten">Hubert Ja Schouten</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>University Hospital, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Van Der Heijde, Dsire Mfm" sort="Van Der Heijde, Dsire Mfm" uniqKey="Van Der Heijde D" first="Dsire Mfm" last="Van Der Heijde">Dsire Mfm Van Der Heijde</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>University Hospital, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Boonen, Annelies" sort="Boonen, Annelies" uniqKey="Boonen A" first="Annelies" last="Boonen">Annelies Boonen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>University Hospital, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Van Der Linden, Sjef" sort="Van Der Linden, Sjef" uniqKey="Van Der Linden S" first="Sjef" last="Van Der Linden">Sjef Van Der Linden</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Pellenberg Hospital, Catholic University, Louvain</wicri:regionArea>
<wicri:noRegion>Louvain</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">The Lancet</title>
<title level="j" type="abbrev">LANCET</title>
<idno type="ISSN">0140-6736</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1997">1997</date>
<biblScope unit="volume">350</biblScope>
<biblScope unit="issue">9074</biblScope>
<biblScope unit="page" from="304">304</biblScope>
<biblScope unit="page" to="305">305</biblScope>
</imprint>
<idno type="ISSN">0140-6736</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Active disease</term>
<term>Additional disease control</term>
<term>Additional effect</term>
<term>Adverse effects</term>
<term>Adverse event</term>
<term>Adverse events</term>
<term>Allocation concealment</term>
<term>American college</term>
<term>Annelies boonen</term>
<term>Antirheumatic</term>
<term>Antirheumatic drugs</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>August</term>
<term>Baseline</term>
<term>Baseline characteristics</term>
<term>Boer</term>
<term>Bone mass</term>
<term>Bridge therapy</term>
<term>Centre</term>
<term>Change scores</term>
<term>Clinical efficacy</term>
<term>Clinical trial</term>
<term>Cobra trial</term>
<term>Combination therapy</term>
<term>Control group</term>
<term>Control visit</term>
<term>Corresponding numbers</term>
<term>Corticosteroid</term>
<term>Crude coefficient</term>
<term>Daily dose</term>
<term>Daily prednisolone dose</term>
<term>Damage score</term>
<term>Disease activity</term>
<term>Disease activity measures</term>
<term>Disease activity score</term>
<term>Disease control</term>
<term>Disease duration</term>
<term>Disease flares</term>
<term>Eligibility criteria</term>
<term>Erosion score</term>
<term>Erosive disease</term>
<term>Femoral neck</term>
<term>First choice</term>
<term>First period</term>
<term>First step</term>
<term>Foot joints</term>
<term>Foot radiographs</term>
<term>Further changes</term>
<term>Gastrointestinal complaints</term>
<term>Global assessment</term>
<term>Grip strength</term>
<term>Group allocation</term>
<term>Health assessment questionnaire</term>
<term>Health professionals</term>
<term>Health status</term>
<term>Heijde</term>
<term>Heijde dmfm</term>
<term>Independent assessment</term>
<term>Independent assessor</term>
<term>Independent assessors</term>
<term>Index values</term>
<term>Joint damage</term>
<term>Joint destruction</term>
<term>Joint destruction recommences</term>
<term>Lancet</term>
<term>Lumbar spine</term>
<term>Maarten boers</term>
<term>Maastricht</term>
<term>Main outcomes</term>
<term>Mcmaster toronto arthritis</term>
<term>Median</term>
<term>Median increase</term>
<term>Medication</term>
<term>Methotrexate</term>
<term>Oral corticosteroids</term>
<term>Oral prednisolone</term>
<term>Other patients</term>
<term>Other studies</term>
<term>Outcome measures</term>
<term>Overall assessment</term>
<term>Parsimonious models</term>
<term>Pharmacia upjohn</term>
<term>Physical function</term>
<term>Piet jacobs</term>
<term>Positive values</term>
<term>Predictive variables</term>
<term>Prednisolone</term>
<term>Primary analysis</term>
<term>Prognostic variables</term>
<term>Progression</term>
<term>Protocol</term>
<term>Protocol treatment</term>
<term>Protocol violations</term>
<term>Pulmonary disease</term>
<term>Radiograph</term>
<term>Radiographic</term>
<term>Radiographic damage</term>
<term>Radiological</term>
<term>Radiological damage</term>
<term>Radiological progression</term>
<term>Randomisation procedure</term>
<term>Randomised</term>
<term>Regimen</term>
<term>Regression analysis</term>
<term>Remission</term>
<term>Research nurse</term>
<term>Results support</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid factor</term>
<term>Rheumatol</term>
<term>Rheumatology</term>
<term>Rheumatology criteria</term>
<term>Riel plcm</term>
<term>Right anchor</term>
<term>Safety committee</term>
<term>Study centre</term>
<term>Study centre coordinator</term>
<term>Study medication</term>
<term>Sulphasalazine</term>
<term>Sulphasalazine group</term>
<term>Total radiological damage score</term>
<term>Total score</term>
<term>Total scores</term>
<term>Toxic effects</term>
<term>Toxicity</term>
<term>Treatment allocation</term>
<term>Treatment assignment</term>
<term>Treatment group</term>
<term>Treatment groups</term>
<term>Treatment protocol</term>
<term>Treatment sulphasalazine</term>
<term>Trial medication</term>
<term>University hospital</term>
<term>University hospital maastricht</term>
<term>Urine samples</term>
<term>Visual analogue scale</term>
<term>Weeks erosion score</term>
<term>Withdrawal rate</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Summary: Background The value of intensive combination therapy in early rheumatoid arthritis is unproven. In a multicentre, double-blind, randomised trial (COBRA), we compared the combination of sulphasalazine (2 g/day), methotrexate (75 mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 75 mg/day) with sulphasalazine alone.Methods 155 patients with early rheumatoid arthritis (median duration 4 months) were randomly assigned combined treatment (76) or sulphasalazine alone (79). Prednisolone and methotrexate were tapered and stopped after 28 and 40 weeks, respectively. The main outcomes were the pooled index (a weighted change score of five disease activity measures) and the Sharp/Van der Heijde radiographic damage score in hands and feet. Independent health-care professionals assessed the main outcomes without knowledge of treatment allocation.Findings At week 28, the mean pooled index was 14 (95 CI 1216) in the combined treatment group and 08 (0610) in the sulphasalazine group (p<00001). At this time, 55 (72) and 39 (49) patients, respectively, were improved according to American College of Rheumatology criteria. The clinical difference between the groups decreased and was no longer significant after prednisolone was stopped, and there were no further changes after methotrexate was stopped. At 28 weeks, the radiographic damage score had increased by a median of 1 (range 028) in the combined-therapy group and 4 (044) in the sulphasalazine group (p<00001). The increases at week 56 (2 [043] vs6 [054], p=0004), and at week 80 (4 [080] vs 12 [072], p=001) were also significant. Further analysis suggests that combined therapy immediately suppressed damage progression, whereas sulphasalazine did so less effectively and with a lag of 6 to 12 months. There were fewer withdrawals in the combined therapy than the sulphasalazine group (6 [8] vs 23 [29]), and they occurred later.Interpretation This combined-therapy regimen offers additional disease control over and above that of sulphasalazine alone that persists for up to a year after corticosteroids are stopped. Although confirmatory studies and long-term follow-up are needed, this approach may prove useful in the treatment of early rheumatoid arthritis.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Belgique</li>
<li>Pays-Bas</li>
</country>
<region>
<li>Hollande-Méridionale</li>
<li>Hollande-Septentrionale</li>
</region>
<settlement>
<li>Amsterdam</li>
<li>Leyde</li>
<li>Rotterdam</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Jacobs, Piet" sort="Jacobs, Piet" uniqKey="Jacobs P" first="Piet" last="Jacobs">Piet Jacobs</name>
<name sortKey="Peeters, Andre J" sort="Peeters, Andre J" uniqKey="Peeters A" first="Andre J" last="Peeters">Andre J. Peeters</name>
<name sortKey="Van Zeben, Derkjen" sort="Van Zeben, Derkjen" uniqKey="Van Zeben D" first="Derkjen" last="Van Zeben">Derkjen Van Zeben</name>
</noCountry>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Boers, Maarten" sort="Boers, Maarten" uniqKey="Boers M" first="Maarten" last="Boers">Maarten Boers</name>
</noRegion>
<name sortKey="Boonen, Annelies" sort="Boonen, Annelies" uniqKey="Boonen A" first="Annelies" last="Boonen">Annelies Boonen</name>
<name sortKey="Dijkmans, Ben Ac" sort="Dijkmans, Ben Ac" uniqKey="Dijkmans B" first="Ben Ac" last="Dijkmans">Ben Ac Dijkmans</name>
<name sortKey="Markusse, Harry M" sort="Markusse, Harry M" uniqKey="Markusse H" first="Harry M" last="Markusse">Harry M. Markusse</name>
<name sortKey="Schouten, Hubert Ja" sort="Schouten, Hubert Ja" uniqKey="Schouten H" first="Hubert Ja" last="Schouten">Hubert Ja Schouten</name>
<name sortKey="Van De Laar, Mart Afj" sort="Van De Laar, Mart Afj" uniqKey="Van De Laar M" first="Mart Afj" last="Van De Laar">Mart Afj Van De Laar</name>
<name sortKey="Van Den Brink, Hans R" sort="Van Den Brink, Hans R" uniqKey="Van Den Brink H" first="Hans R" last="Van Den Brink">Hans R. Van Den Brink</name>
<name sortKey="Van Denderen, J Christiaan" sort="Van Denderen, J Christiaan" uniqKey="Van Denderen J" first="J Christiaan" last="Van Denderen">J Christiaan Van Denderen</name>
<name sortKey="Van Der Heijde, Dsire Mfm" sort="Van Der Heijde, Dsire Mfm" uniqKey="Van Der Heijde D" first="Dsire Mfm" last="Van Der Heijde">Dsire Mfm Van Der Heijde</name>
<name sortKey="Verhoeven, Arco C" sort="Verhoeven, Arco C" uniqKey="Verhoeven A" first="Arco C" last="Verhoeven">Arco C. Verhoeven</name>
</country>
<country name="Belgique">
<noRegion>
<name sortKey="Westhovens, Rene" sort="Westhovens, Rene" uniqKey="Westhovens R" first="Rene" last="Westhovens">Rene Westhovens</name>
</noRegion>
<name sortKey="Van Der Linden, Sjef" sort="Van Der Linden, Sjef" uniqKey="Van Der Linden S" first="Sjef" last="Van Der Linden">Sjef Van Der Linden</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002869 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002869 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F5B9214CDA21717C12528C07FBCFABD67ECA8770
   |texte=   Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021